


Accepted Manuscript

DHA-enriched fish oil upregulates cyclin-dependent kinase inhibitor 2A (P16^{INK}) expression and downregulates telomerase activity without modulating effects of PPAR γ Pro12Ala polymorphism in type 2 diabetic patients: A randomized, double-blind, placebo-controlled clinical trial



Omid Toupchian, PhD, Gity Sotoudeh, PhD, Anahita Mansoori, PhD, Shima Abdollahi, MSc, Seyyed Ali Keshavarz, PhD, Mahmoud Djalali, PhD, Ensieh Nasli-Esfahani, MD, Ehsan Alvandi, MSc, Reza Chahardoli, MSc, Fariba Koohdani, PhD

PII: S0261-5614(16)31348-6

DOI: [10.1016/j.clnu.2016.12.007](https://doi.org/10.1016/j.clnu.2016.12.007)

Reference: YCLNU 2997

To appear in: *Clinical Nutrition*

Received Date: 30 May 2016

Revised Date: 8 December 2016

Accepted Date: 8 December 2016

Please cite this article as: Toupchian O, Sotoudeh G, Mansoori A, Abdollahi S, Keshavarz SA, Djalali M, Nasli-Esfahani E, Alvandi E, Chahardoli R, Koohdani F, DHA-enriched fish oil upregulates cyclin-dependent kinase inhibitor 2A (P16^{INK}) expression and downregulates telomerase activity without modulating effects of PPAR γ Pro12Ala polymorphism in type 2 diabetic patients: A randomized, double-blind, placebo-controlled clinical trial, *Clinical Nutrition* (2017), doi: 10.1016/j.clnu.2016.12.007.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **DHA-enriched fish oil upregulates cyclin-dependent kinase inhibitor 2A**
2 **(P16^{INK}) expression and downregulates telomerase activity without**
3 **modulating effects of PPAR γ Pro12Ala polymorphism in type 2 diabetic**
4 **patients: A randomized, double-blind, placebo-controlled clinical trial**

5
6
7 **Authors:** Omid Toupchian¹ (PhD), Gity Sotoudeh^{2*}(PhD), Anahita Mansoori^{3,1}(PhD),
8 Shima Abdollahi⁴ (MSc), Seyyed Ali Keshavarz⁵ (PhD), Mahmoud Djalali¹ (PhD), Ensieh
9 Nasli-Esfahani⁶ (MD), Ehsan Alvandi¹ (MSc), Reza Chahardoli¹ (MSc), Fariba
10 Koohdani^{6,1*} (PhD)

11
12
13 1: Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and
14 Dietetics, Tehran University of Medical Sciences, Tehran, Iran

15 2: Department of Community Nutrition, School of Nutritional Sciences and Dietetics,
16 Tehran University of Medical Sciences, Tehran, Iran

17 3: Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of
18 Medical Sciences, Ahvaz, Iran

19 4: Department of Nutrition, Faculty of Health, Shahid Sadoughi University of Medical
20 Sciences, Yazd, Iran

21 5: Clinical Nutrition Department, School of Nutritional Science and Dietetics, Tehran
22 University of Medical Sciences, Tehran, Iran

23 6: Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences
24 Institute, Tehran University of Medical Sciences, Tehran, Iran Clinical Nutrition

25
26
27 * These two authors contributed equally to work

28
29
30 Address all correspondence and requests for reprints to: Fariba Koohdani, Diabetes
31 Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran
32 University of Medical Sciences, Tehran, Iran

Download English Version:

<https://daneshyari.com/en/article/8586880>

Download Persian Version:

<https://daneshyari.com/article/8586880>

[Daneshyari.com](https://daneshyari.com)